Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families

被引:5
|
作者
Bonache, Sandra [1 ,2 ]
Gutierrez-Enriquez, Sara [1 ]
Tenes, Anna [1 ]
Masas, Miriam [1 ,2 ]
Balmana, Judith [3 ]
Diez, Orland [1 ,2 ,4 ]
机构
[1] Univ Autonoma Barcelona, Vall dHebron Inst Oncol VHIO, Oncogenet Lab, Barcelona 08035, Spain
[2] Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Oncogenet Lab, Barcelona 08035, Spain
[3] Univ Autonoma Barcelona, Univ Hosp Vall dHebron, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona 08035, Spain
[4] Univ Hosp Vall dHebron, Oncogenet Lab, Barcelona, Spain
关键词
BCCIP; Familial breast/ovarian cancer; Mutational analysis; HOMOLOGOUS RECOMBINATION; ALLELIC LOSS; DNA-DAMAGE; BRCA2; PROTEIN; RAD51; CHROMOSOME-10; CYTOKINESIS; EXPRESSION; SUGGESTS;
D O I
10.1016/j.ygyno.2013.07.104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. About 5%-10% of breast cancer is due to inherited disease predisposition. Currently, mutations in the BRCA1 and BRCA2 genes explain less than 25% of the familial clustering of breast cancer, and additional susceptibility genes are suspected. The BCCIP gene plays an important role in the regulation of gene transcription and cell proliferation and could be involved in the maintenance of genomic integrity. The BCCIP protein binds in mammalian cells to the longest conserved region of the BRCA2 protein and is required for BRCA2 stability and function, making a critical contribution to the function of BRCA2 in mediating homologous recombination. Variants in the BCCIP gene could affect the BRCA2 functionality and be associated to the familial breast/ovarian carcinogenesis. Therefore, BCCIP gene is a potential candidate for being involved in heritable cancer susceptibility. Methods. We have screened the entire coding region and splice junctions of BCCIP in affected index cases from 215 Spanish breast/ovarian cancer families for germ line defects, using direct sequencing. Results. Mutation analysis revealed 3 different intronic sequence changes. Conclusions. Based on the in silico and in vitro RNA analyses of these sequence alterations, none of them were predicted to be pathogenic or associated with cancer susceptibility. Our results indicate that BCCIP germ line mutations are unlikely to be a major contributor to familial breast/ovarian cancer risk in our population. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:460 / 463
页数:4
相关论文
共 50 条
  • [31] Analysis of the DOK1 gene in breast cancer
    Tuna, Esin
    Ersoy, Yeliz Emine
    Bulut, Pelin
    Ozdemir, Filiz
    Buyru, Nur
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (03) : 1605 - 1612
  • [32] Genetic alterations of the WWOX gene in breast cancer
    Ekizoglu, Seda
    Muslumanoglu, Mahmut
    Dalay, Nejat
    Buyru, Nur
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1529 - 1535
  • [33] Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer
    Robinson, Dan R.
    Kalyana-Sundaram, Shanker
    Wu, Yi-Mi
    Shankar, Sunita
    Cao, Xuhong
    Ateeq, Bushra
    Asangani, Irfan A.
    Iyer, Matthew
    Maher, Christopher A.
    Grasso, Catherine S.
    Lonigro, Robert J.
    Quist, Michael
    Siddiqui, Javed
    Mehra, Rohit
    Jing, Xiaojun
    Giordano, Thomas J.
    Sabel, Michael S.
    Kleer, Celina G.
    Palanisamy, Nallasivam
    Natrajan, Rachael
    Lambros, Maryou B.
    Reis-Filho, Jorge S.
    Kumar-Sinha, Chandan
    Chinnaiyan, Arul M.
    NATURE MEDICINE, 2011, 17 (12) : 1646 - U163
  • [34] [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status
    Weeks, Joanna K.
    Pantel, Austin R.
    Gitto, Sarah B.
    Liu, Fang
    Schubert, Erin K.
    Pryma, Daniel A.
    Farwell, Michael D.
    Mankoff, David A.
    Mach, Robert H.
    Simpkins, Fiona
    Lin, Lilie L.
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 34 - 39
  • [35] No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers
    Moller, Pal
    Maehle, Lovise
    Clark, Neal
    Apold, Jaran
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2007, 5 (02) : 67 - 71
  • [36] No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
    Pål Møller
    Lovise Mæhle
    Neal Clark
    Jaran Apold
    Hereditary Cancer in Clinical Practice, 5
  • [37] Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
    Hartley, Taila
    Cavallone, Luca
    Sabbaghian, Nelly
    Silva-Smith, Rachel
    Hamel, Nancy
    Aleynikova, Olga
    Smith, Erika
    Hastings, Valerie
    Pinto, Pedro
    Tischkowitz, Marc
    Tomiak, Eva
    Foulkes, William D.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2014, 12
  • [38] Association of LAPTM4B gene polymorphism with breast cancer susceptibility
    Fan, Meirong
    Liu, Ye
    Zhou, Rouli
    Zhang, Qingyun
    CANCER EPIDEMIOLOGY, 2012, 36 (04) : 364 - 368
  • [39] CD243 gene polymorphism significantly associated with breast cancer susceptibility
    Yao, Weirong
    Yan, Rongzeng
    Ma, Lin
    Wan, Huiping
    Yu, Yanmin
    Cheng, Xia
    Li, Yingliang
    TUMOR BIOLOGY, 2014, 35 (08) : 8017 - 8022
  • [40] Analysis of 17β-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer
    Plourde, Marie
    Ferland, Alexandra
    Soucy, Penny
    Hamdi, Yosr
    Tranchant, Martine
    Durocher, Francine
    Sinilnikova, Olga
    The, Van Luu
    Simard, Jacques
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2009, 116 (3-5) : 134 - 153